Recipharm has partnered with Laccure AB for the commercial manufacture and delivery of Laccure Pessary.

The new product, which has been developed to help women suffering from bacterial vaginosis, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga, Sweden, that specializes in the production of semi-solid products.

Over the past years, Laccure AB has taken the product from innovation through clinical studies to commercial manufacturing. The development work was focused on creating an effective antibiotic-free product that was also user-friendly in terms of being easy to apply and not messy to use.

Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure Pessary and the exact date for the launch will be announced next year.

Laccure AB is a project company within the life science development organization Partners for Development Investments in Life Sciences (P.U.L.S.). As it prepares for launch, the owner is looking to sell the company to a buyer with the resources required to bring the product to market.

“We are delighted to be collaborating with Recipharm, they are an expert partner that we can rely on for the commercial supply of our new product,” said Jeanette Robertsson, chief executive officer, Laccure AB. “Given the potential market for the product, a major benefit of partnering with Recipharm is that they have a high level of production capacity, which of course gives us the possibility to further scale up the batch size to meet market requirements in the future.”

Laccure Pessary is based on a patented substance that releases lactic acid, and only needs to be administered once to treat a bacterial vaginosis infection and then once a month to prevent a recurrence.

Ingela Palmkvist, general manager, Recipharm Karlskoga, said, “We are really looking forward to the commercial launch of this product, and contributing to something that will make a major difference to the lives of many women across the globe.”